Generare Raises €20M for AI Molecular Discovery

Paris-based Generare has successfully closed a significant €20 million Series A funding round, injecting capital to fuel its ambitious expansion in AI-driven molecular discovery. The investment, co-led by prominent venture capital firms Alven and Daphni, underscores the growing investor confidence in novel approaches to pharmaceutical and agrochemical research. This latest infusion of capital follows an earlier €5 million raise in October 2024, signaling strong momentum for the young biotechnology firm.

Founded in 2023 by Guillaume Vandenesch and Vincent Libis, Generare is tackling a fundamental bottleneck in drug development: the scarcity of truly novel molecular starting points. The company leverages advanced artificial intelligence to mine the vast, largely untapped potential within microbial genomes. These microbial sources, representing an estimated 97% of genomic data yet to be explored by humanity, are rich with evolutionary innovations that Generare's platform is designed to unlock.

Generare's core innovation lies in its ability to construct an unparalleled database of undiscovered molecular chemistry. By focusing on small molecules – the bedrock of the vast majority of contemporary pharmaceuticals – the company aims to provide researchers with a critical advantage. In 2025 alone, Generare reported the discovery of over 200 novel molecules, a figure that significantly outpaces the combined output of many competitors who collectively identified only dozens. This substantial lead highlights the efficacy of their AI-driven methodology.

“The drug discovery process is fundamentally hampered by a data deficit. The industry often relies on a limited pool of existing chemical structures, leading to repetitive research pathways and predictable outcomes,” stated CEO Guillaume Vandenesch. “Our mission is to equip laboratories and their computational tools with a fresh, high-quality, and genuinely original molecular dataset, breaking free from these conventional limitations.”

The newly secured funds will be instrumental in scaling Generare's discovery operations and significantly expanding its expert team. The company plans to double its current headcount of 25, bringing on board additional computational biologists, chemists, synthetic biologists, and engineers. This strategic hiring will support their aggressive target to increase discovery capacity tenfold by 2027, aiming to identify over 2,000 new molecules, with a long-term vision exceeding 10,000 unique compounds.

The implications for the pharmaceutical and agrochemical sectors are substantial. Generare's proprietary dataset of novel small molecules offers a powerful new resource for companies seeking innovative leads in areas such as new drug candidates and advanced crop protection solutions. The market for novel small molecules is critical, with the global drug discovery market projected to reach hundreds of billions of dollars in the coming years, driven by the constant need for more effective and targeted therapies.

The Series A round saw participation from existing investors including Galion.exe, Teampact Ventures, and VIVES Partners, demonstrating continued support and belief in Generare's vision. This strong backing from both new and existing stakeholders positions Generare to make a significant impact on the future of molecular discovery.